UPDATE 1-U.S. appeals court upholds ruling invalidating J&J patent on Remicade [Reuters]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Reuters
UPDATE 1-U.S. appeals court upholds ruling invalidating J&J patent on Remicade | Reuters Reuters Staff 2 Min Read (Adds details) By Jan Wolfe Jan 23 (Reuters) - A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J’s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug. The U.S. Circuit Court of Appeals for the Federal Circuit affirmed a ruling by a U.S. administrative court that a J&J patent covering the active ingredient in Remicade was invalid because its concepts were covered in a prior J&J patent. Representatives of J&J and Pfizer did not immediately respond to requests for comment on the ruling. Remicade generated U.S. sales of $4.8 billion for J&J in 2016 but faces increased competition from cheaper “biosimilar” copycats, including Pfizer’s version, which is sold in the U.S. under the name Inflectra. Pfizer launched Inflectra i
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Medical device maker Intuitive beats estimates on strong demand for surgical robots [Yahoo! Finance]Yahoo! Finance
- Global Anti-hypertensive Drug Market Size To Exceed USD 50 Billion By 2033 | CAGR of 7.18% [Yahoo! Finance]Yahoo! Finance
- Denis Johnson Joins Kindeva Drug Delivery as Chief Operating Officer to Lead Global Operations [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson (NYSE: JNJ) was upgraded by analysts at HSBC Holdings plc from a "hold" rating to a "buy" rating. They now have a $170.00 price target on the stock.MarketBeat
- Global Specimen Retrieval Market Size To Exceed USD 0.52 Billion By 2033 | CAGR of 4.97% [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 4/16/24 - Beat
JNJ
Sec Filings
- 4/16/24 - Form 8-K/A
- 4/16/24 - Form 8-K
- 3/27/24 - Form PX14A6G
- JNJ's page on the SEC website